SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-019449
Filing Date
2022-10-11
Accepted
2022-10-11 17:22:21
Documents
12
Period of Report
2022-10-07
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K eypt-20221007.htm   iXBRL 8-K 50789
  Complete submission text file 0000950170-22-019449.txt   163657

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eypt-20221007_pre.xml EX-101.PRE 9457
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eypt-20221007.xsd EX-101.SCH 2475
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eypt-20221007_lab.xml EX-101.LAB 12806
6 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20221007_htm.xml XML 4523
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 221304832
SIC: 3826 Laboratory Analytical Instruments